Momenta Pharma (MNTA) 11.80 $MNTA Momenta

New Post Public Reply Private Reply Replies (0) Message Board

Jun 10, 2016 at 10:13 AM

Momenta Pharma (MNTA) 11.80 $MNTA

Momenta Pharmaceuticals Initiates Phase 1 Trial of M281, an Anti-FcRn Monoclonal Antibody
GlobeNewswire - Thu Jun 09, 7:00AM CDT
Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today announced the dosing of the first healthy volunteers in a Phase 1 randomized, double-blind, placebo-controlled, ascending-dose cohort study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of M281, an anti-FcRn monoclonal antibody, for the treatment of autoimmune diseases.
MNTA: 11.80 (unch)

Shares of MNTA Up 26.9% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Thu Jun 09, 1:03AM CDT
SmarTrend identified an Uptrend for Momenta Pharmaceuticals (NASDAQ:MNTA) on April 4th, 2016 at $9.55. In approximately 2 months, Momenta Pharmaceuticals has returned 26.91% as of today's recent price of $12.12.
MNTA: 11.80 (unch)

Momenta Pharmaceuticals Announces Data Presentation on M923, a Proposed HUMIRA(R) (adalimumab) Biosimilar, at EULAR 2016
GlobeNewswire - Wed Jun 08, 7:00AM CDT
Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today announced that key data from a pharmacokinetic/safety study of M923, the Company's lead biosimilar candidate developed in collaboration with Baxalta, now part of Shire plc, will be presented at the European League Against Rheumatism Annual Congress (EULAR) 2016 Annual Meeting in London.
SHPG: 179.08 (-4.87), MNTA: 11.80 (unch)

Momenta Pharmaceuticals Announces Presentation of Final Data from Phase 1 Trial of Necuparanib in Patients with Pancreatic Cancer at ASCO
GlobeNewswire - Sat Jun 04, 8:00AM CDT
Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today presented final data from the Phase 1 trial evaluating necuparanib in combination with nab-paclitaxel (nabP; Abraxane) and gemcitabine (gem) in patients with advanced metastatic pancreatic cancer (ClinicalTrials.gov Identifier NCT01621243) at the 2016 ASCO Annual Meeting, from 8:00 to 11:30 am CDT (Abstract #4117 / Poster #109) in Chicago, IL.
MNTA: 11.80 (unch)

Momenta Pharmaceuticals Shares Up 26.4% Since SmarTrend's Buy Recommendation (MNTA)
Comtex SmarTrend(R) - Wed Jun 01, 1:35PM CDT
SmarTrend identified an Uptrend for Momenta Pharmaceuticals (NASDAQ:MNTA) on April 4th, 2016 at $9.55. In approximately 2 months, Momenta Pharmaceuticals has returned 26.39% as of today's recent price of $12.07.
MNTA: 11.80 (unch)

Momenta Pharmaceuticals to Webcast Presentation at the Goldman Sachs 37th Annual Global Healthcare Conference
GlobeNewswire - Wed May 25, 7:00AM CDT
Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today announced that its presentation at the Goldman Sachs 37 Annual Healthcare Conference will be webcast on Wednesday, June 8 at 8 a.m. PT.
MNTA: 11.80 (unch)

Rexahn's Drugs Deal a Death Blow to Solid Tumor Cancer
ACCESSWIRE - Thu May 19, 8:01AM CDT
Efficacy in Gemzar-resistant cancer is proven
RNN: 0.28 (unch), OGXI: 1.08 (+0.07), AMGN: 155.78 (-1.00), LLY: 73.60 (-0.83), BMY: 72.74 (+0.01), MNTA: 11.80 (unch), CELG: 105.27 (-0.86), EXEL: 7.41 (+0.04)

Momenta Pharmaceuticals Announces Data Presentation on Necuparanib at the 2016 ASCO Annual Meeting
GlobeNewswire - Thu May 19, 7:00AM CDT
Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today announced the upcoming presentation of its final results from the Phase 1 study of its drug candidate, necuparanib, in patients with metastatic pancreatic cancer. The poster will be presented at the upcoming American Society of Clinical Oncology (ASCO) 2016 Annual Meeting.
MNTA: 11.80 (unch)

Momenta (MNTA) Reports Narrower-than-Expected Q1 Loss
Zacks Equity Research - Zacks Investment Research - Wed May 04, 2:20PM CDT
Momenta Pharmaceuticals Inc. (MNTA) reported a loss of 35 cents per share in the first quarter of 2016, narrower than both the Zacks Consensus Estimate of a loss of 38 cents and the year-ago loss of 40 cents.
SHPG: 179.08 (-4.87), MYL: 43.70 (-2.06), BXLT: 46.02 (-0.18), MNTA: 11.80 (unch)

Momenta reports 1Q loss
Automated Insights - Tue May 03, 7:26AM CDT
CAMBRIDGE, Mass. (AP) _ Momenta Pharmaceuticals Inc. (MNTA) on Tuesday reported a loss of $24 million in its first quarter.
MNTA: 11.80 (unch)

Momenta Pharmaceuticals Reports First Quarter 2016 Financial Results
GlobeNewswire - Tue May 03, 7:00AM CDT
Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA) today reported its financial results for the first quarter ended March 31, 2016.
MNTA: 11.80 (unch)

Momenta Pharmaceuticals Announces Time Change for First Quarter 2016 Financial Results Conference Call and Webcast
GlobeNewswire - Tue Apr 26, 7:00AM CDT
Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA), announced today that is has changed the time for its first quarter 2016 earnings conference call and webcast. Momenta will now host its conference call and webcast at 9:00 a.m. EDT on Tuesday, May 3, 2016.
MNTA: 11.80 (unch)

Momenta Pharmaceuticals to Webcast Presentation at Two Upcoming Investor Conferences
GlobeNewswire - Mon Apr 25, 7:00AM CDT
Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today announced that it will webcast its presentation at two upcoming investor conferences.
DB: 15.92 (-0.79), MNTA: 11.80 (unch)

Momenta Pharmaceuticals Announces Date of First Quarter 2016 Financial Results Conference Call and Webcast
GlobeNewswire - Tue Apr 19, 7:00AM CDT
Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, will release its financial results for the first quarter ended March 31, 2016 before the U.S. financial markets open on Tuesday, May 3, 2016.
MNTA: 11.80 (unch)

9 Things You Need to Know About Biosimilar Drugs
Brian Orelli, The Motley Fool - Motley Fool - Mon Mar 28, 1:59PM CDT
It's not often that investors get an opportunity to invest in a whole new class of drugs, but they've got an opportunity to invest on the ground floor with biosimilars. Last year, the Food and Drug Administration approved the first biosimilar drug, ...
BIIB: 248.72 (-1.74), MYL: 43.70 (-2.06), AMGN: 155.78 (-1.00), TEVA: 52.53 (-0.78), MNTA: 11.80 (unch), NVS: 79.16 (-1.35)

Should You Get Rid of Momenta Pharmaceuticals (MNTA) Now?
Zacks Equity Research - Zacks Investment Research - Mon Mar 14, 7:31AM CDT
Momenta Pharmaceuticals has witnessed a significant price decline in the past four weeks and negative estimate revisions, making it time for investors to sell it off
ANIK: 49.02 (+0.10), MNTA: 11.80 (unch)

Biotech Investing Guide: 3 Stocks to Buy and 3 to Avoid
Arpita Dutt - Zacks Investment Research - Fri Mar 11, 8:37AM CST
Is the dream run for the biotech sector finally over?
GILD: 85.03 (-0.74), AMGN: 155.78 (-1.00), ABBV: 60.45 (-0.30), MNTA: 11.80 (unch), ARNA: 2.02 (-0.04), REGN: 375.99 (-5.09), CELG: 105.27 (-0.86)

Momenta Pharmaceuticals Inc. Shed a Third of Its Value in February -- Here's Why
Sean Williams, The Motley Fool - Motley Fool - Fri Mar 04, 4:19PM CST
What: Shares of Momenta Pharmaceuticals , a biopharmaceutical company focused on the development of generic and biosimilar drugs for oncology and autoimmune diseases, shed 33% of their value in February, based on data from S&P Global Market...
MNTA: 11.80 (unch)

Shares of MNTA Down 43.6% Since Downtrend Call on Shares
Comtex SmarTrend(R) - Thu Mar 03, 9:25AM CST
SmarTrend identified a Downtrend for Momenta Pharmaceuticals (NASDAQ:MNTA) on December 11th, 2015 at $15.84. In approximately 3 months, Momenta Pharmaceuticals has returned 43.62% as of today's recent price of $8.93.
MNTA: 11.80 (unch)

Momenta Blocked
Brian Orelli, The Motley Fool - Motley Fool - Fri Feb 19, 3:20PM CST
Momenta Pharmaceuticals released fourth-quarter earnings on Thursday with all eyes on sales of Glatopa, its generic version of Teva Pharmaceuticals ' Copaxone. Momenta Pharmaceuticals results: The raw numbers Q4 2015 Actuals ...
TEVA: 52.53 (-0.78), MNTA: 11.80 (unch), NVS: 79.16 (-1.35)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Duke Energy Braces for Isaias: Key Prep Steps Ahead

Brace Yourself: Duke Energy Gears Up for Isaias In the ever-unpredictable game of Mother Nature versus infrastructure, Duke Energy is stepping into the ring once more, readying to tackle potential outages across the Carolinas as Hurricane Isaias edges near. Listen, if there's one thing I've learned over years of watching these weather events unfold on the stock ticker and...

TKO's Bold $2B All-Cash Move for SVC's Hotels

TKO's Big, Bold Bid: What Does it Mean? In the crazy world of high-stakes hospitality investments, there are moments that turn heads. TKO's $2 billion all-cash offer to snag Service Properties Trust's prized hotel portfolio is exactly one of those shake-ups. Let's not sugarcoat it; this is a bold move to the big leagues, and it's not without its quirks. A Cash-Infused...

BETR Faces Securities Fraud Actions Post-Misleading Statements

Unpacking the Legal Drama Around BETR The tale of Better Home & Finance Holding Company (BETR) is like a roadside crash you can't help but stare at. We're talking big, ugly losses and a chance for investors who got roughed up to throw some punches back with a securities fraud class action. The legal honchos at Howard G. Smith's law office are rallying the troops. If...

HackerOne Finds Cybersecurity Challenges in Exposure Debt

Understanding the Implications of 'Exposure Debt' When you hear about 'exposure debt', it's not just tech jargon—it's a core issue hacking at the very safety nets companies rely on. This term, highlighted in HackerOne's latest Security Research Report, marks a stark reality in cybersecurity. The backlog of verified yet unresolved vulnerabilities surged a whopping 131%...

Moore, Schulman & Moore Attorneys Earn Top Honors Again

In the realm of family law, consistency in excellence matters just as much as landing a high-stakes stock trade. Moore, Schulman & Moore, APC, a San Diego family law outfit, has grabbed the spotlight yet again with nine of its ace attorneys snagging recognition from the 2027 Super Lawyers roster. A Tradition of Professional Recognition Leading the pack is Erik Moore, a...

STRATA Showcases Excimer Laser Success in Dermatology

The Cutting Edge of Skin Care: STRATA's Spotlight It's not every day you hear about dermatology shaking things up, but STRATA Skin Sciences, Inc. pulled it off with flair at the 2026 Fall Clinical Dermatology Conference in Las Vegas. For 'skin in the game,' these folks are leading the charge with their innovative excimer laser phototherapy approach, shining a fresh light...

Mastering Packaging Costs: Beyond the Box Price

Peeling Back the Layers of Packaging Costs Packaging's a bit like an onion—every layer you peel back reveals another cost you didn’t see at first glance. Folks in the know, like Kyle Reger of Jamestown Container Companies, are flipping the script on how we approach packaging expenses. It's not just about snagging the cheapest box on the shelf anymore. There's a whole...

Bill Evans Enhances Gateway's Wealth Management Expertise

Welcome Aboard, Bill Evans Some days the financial world throws a gem your way, something worth more than a rat-race racehorse in a shattered stock rally. Meet Bill Evans, a seasoned professional stepping into the vibrant arena of Gateway Financial Partners. He’s put in 29 years around the investment block, and now he’s parking himself in Glastonbury, Connecticut, set...

AI Visibility: A Game Changer for SEO in 2027?

AI Changes the SEO Game Rank Math, the brains behind a trusty WordPress SEO plugin, has thrown a bold prediction at us: AI visibility is set to become a standard SEO metric next year. Gurugram, India, saw this gem of an announcement on October 9, 2026. So, what's ticking here? Consumers, more than ever, are resting on AI-generated answers to make decisions. It's like...

Zenni and Chase Stokes Foster Student Wellbeing in NYC

Picture this: near 300 high schoolers milling around, glancing through shiny new glasses from the Zenni x Chase Stokes collection. In the heart of New York City, these kids are getting a double-dose of care that's all too rare—free vision screenings paired with mental health support. It's the kind of collaboration that shows you what's possible when a company, an actor,...